Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) - Stock analysts at Zacks Research decreased their Q1 2025 EPS estimates for shares of Vertex Pharmaceuticals in a research report issued to clients and investors on Thursday, January 23rd. Zacks Research analyst R. Department now expects that the pharmaceutical company will post earnings per share of $3.51 for the quarter, down from their previous forecast of $3.82. The consensus estimate for Vertex Pharmaceuticals' current full-year earnings is ($1.90) per share. Zacks Research also issued estimates for Vertex Pharmaceuticals' Q2 2025 earnings at $3.76 EPS.
Other equities analysts have also recently issued research reports about the stock. Cantor Fitzgerald reissued an "overweight" rating and issued a $480.00 price target on shares of Vertex Pharmaceuticals in a research note on Friday. Scotiabank increased their target price on Vertex Pharmaceuticals from $426.00 to $430.00 and gave the company a "sector perform" rating in a research note on Monday, December 23rd. HC Wainwright dropped their price target on Vertex Pharmaceuticals from $600.00 to $535.00 and set a "buy" rating for the company in a research note on Friday, December 20th. BMO Capital Markets decreased their price objective on Vertex Pharmaceuticals from $566.00 to $520.00 and set an "outperform" rating on the stock in a report on Friday, December 20th. Finally, Truist Financial reduced their price target on shares of Vertex Pharmaceuticals from $550.00 to $460.00 and set a "buy" rating on the stock in a research report on Monday, December 23rd. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $494.84.
Check Out Our Latest Stock Report on Vertex Pharmaceuticals
Shares of NASDAQ VRTX opened at $439.62 on Monday. The business has a 50-day moving average of $435.36 and a 200-day moving average of $464.51. The firm has a market capitalization of $113.21 billion, a price-to-earnings ratio of -220.91, a PEG ratio of 2.20 and a beta of 0.40. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals has a 12 month low of $377.85 and a 12 month high of $519.88.
Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The company had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. During the same quarter last year, the company earned $3.67 earnings per share. The firm's quarterly revenue was up 11.6% on a year-over-year basis.
Hedge funds have recently modified their holdings of the business. Northwest Investment Counselors LLC bought a new stake in Vertex Pharmaceuticals during the third quarter worth about $25,000. Highline Wealth Partners LLC bought a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter worth approximately $27,000. Dunhill Financial LLC grew its stake in shares of Vertex Pharmaceuticals by 70.6% in the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company's stock worth $27,000 after buying an additional 24 shares during the last quarter. Legacy Investment Solutions LLC bought a new position in Vertex Pharmaceuticals during the 3rd quarter valued at approximately $33,000. Finally, Truvestments Capital LLC purchased a new position in Vertex Pharmaceuticals during the third quarter valued at $35,000. Institutional investors own 90.96% of the company's stock.
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Vertex Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.
While Vertex Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.